12,424
Participants
Start Date
April 24, 2017
Primary Completion Date
February 18, 2022
Study Completion Date
February 18, 2022
Acetylsalicylic acid
The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.
Low Molecular Weight Heparin (LMWH)
The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
Allegheny General Hospital, Pittsburgh
University of Maryland R Adams Cowley Shock Trauma Center, Baltimore
Inova Fairfax Hospital, Falls Church
Wake Forest University Baptist Medical Center, Winston-Salem
Carolinas Medical Center, Charlotte
University of Miami Ryder Trauma Center, Miami
Vanderbilt Medical Center, Nashville
University of Tennessee, RegionOne Medical Center, Memphis
University of Mississippi Medical Center, Jackson
MetroHealth Medical Center, Cleveland
Methodist Hospital, Indianapolis
University of Wisconsin, Madison
University of Texas Health Science Center at Houston, Houston
San Antonio Military Medical Center, San Antonio
University of Arizona, Tucson
Harborview Medical Center, Seattle
Massachusetts General Hospital, Boston
Dartmouth-Hitchcock Medical Center, Lebanon
Rhode Island Hospital, Brown University, Providence
University of Calgary, Foothills Medical Centre, Calgary
McMaster University, Hamilton General Hospital, Hamilton
Patient-Centered Outcomes Research Institute
OTHER
Major Extremity Trauma Research Consortium
OTHER